富蘭克林坦伯頓全球投資系列-生技領航基金美元A(acc)股
43.64美元0.24(0.55%)
2024/10/04更新
該基金的投資目標為資本增值。該基金主要地投資位於美國及其他國家的生物科技公司和研究發展公司的股份,及在較少程度上投資於全世界任何類別的機構所發行的債務證券。就該基金的投資目標而言,生物科技公司是指其最少50%的盈利乃由生物科技業務所提供,或公司在最近的財政年度將至少50%的資產投資發展該等業務。
大型 | |||
---|---|---|---|
中型 | |||
小型 | |||
價值型 | 均衡型 | 增長型 |
Mr. Felt has been a portfolio manager, providing research and advice on the purchases and sales of individual securities and portfolio risk assessment. He joined Franklin Templeton in 2018. Prior to joining Franklin Templeton, Mr. Felt was a Senior Research Analyst with Asymmetry Capital, a healthcare focused hedge fund. He has covered the biotechnology sector since 2007 in increasing capacities on the sell-side, most recently as Managing Director for Oppenheimer & Co.
Mr. McCulloch, CFA, joined Franklin Templeton Investments in 1992.
基金篩選
沒有符合 ”“ 的搜尋結果。